Tuberculosis Exposure Detection and Management
Primary Testing Options
- The Centers for Disease Control and Prevention (CDC) recommends using either the Tuberculin Skin Test (TST) or Interferon-Gamma Release Assays (IGRAs) to detect prior exposure to tuberculosis, with the choice of test depending on specific patient factors 1, 2
- The TST involves intradermal injection of purified protein derivative (PPD) tuberculin, with measurement of induration after 48-72 hours, and an induration diameter ≥5 mm is considered positive for any contact of an infectious TB case 3
- IGRAs, such as QuantiFERON-TB Gold (QFT-G), measure interferon-gamma release from lymphocytes when blood is incubated with M. tuberculosis-specific proteins, and are unaffected by BCG vaccination and most non-tuberculous mycobacteria, providing greater specificity than TST 1, 4, 5
When to Use Each Test
- The CDC prefers IGRA over TST in patients with prior BCG vaccination, as TST produces false-positives in this population, and in situations where patient return for TST reading is unlikely, or in patients already on immunosuppressive therapy 2, 5, 6
- Either test can be used for contact investigations, and a positive result from either test should prompt the same evaluation and management 1, 2
Critical Testing Timing
- The CDC recommends testing all contacts without documented prior TB or latent TB infection (LTBI) at initial encounter, ideally within 7 days for high-priority contacts, and repeat testing 8-10 weeks after the last exposure if the initial test is negative 2, 3
- A negative test obtained <8 weeks after exposure is unreliable for excluding infection, as it reflects the window period required for the immune system to mount a detectable response after M. tuberculosis exposure 3, 7
Important Clinical Caveats
- Persons with documented prior LTBI or TB disease do not need repeat testing after exposure, but should be evaluated clinically if TB disease is suspected 2, 8
- Both QFT-G and TST may be less sensitive in severely immunosuppressed adults, children <5 years, or patients about to receive TNF-α inhibitors, and a negative result alone should not exclude M. tuberculosis infection in these high-risk groups 1
- A positive TST in a BCG-vaccinated contact of an infectious TB case should be interpreted as evidence of recent M. tuberculosis infection, not just vaccine effect, and TST may be false-negative in patients on corticosteroids >1 month or immunomodulators >3 months 3, 5
Timing of IGRA Testing After Tuberculosis Exposure
Initial Testing
- The CDC recommends performing an IGRA (or TST) as soon as exposure is recognized, ideally within the first week for high‑priority contacts, and recording the date of the last exposure. 9
Repeat‑Testing Timing
- For contacts with an initially negative IGRA performed less than 8 weeks after the last exposure, the CDC mandates a repeat IGRA 8–10 weeks after the end of exposure to capture conversions that may occur during the immunologic window period. [9][10]
- The CDC explicitly advises repeat testing at 8–10 weeks after exposure for all contacts with an initial negative IGRA, acknowledging that precise IGRA conversion timing data are lacking. [9][10]
Test Consistency
- The same IGRA platform should be used for the repeat test to avoid apparent conversions caused by methodological differences rather than true infection. [9][10]
Special Populations
- Individuals with documented prior latent TB infection (LTBI) or past TB disease do not require repeat IGRA testing after a new exposure, though they should receive a clinical evaluation if active TB is suspected. 11
- In severely immunocompromised contacts (e.g., HIV‑infected persons, children < 5 years, or patients initiating TNF‑α antagonists), a negative IGRA—even when performed at 8–10 weeks—should not be considered definitive for ruling out infection because test sensitivity is reduced in these groups. 12
Rationale and Evidence
- The 8–10‑week repeat‑testing interval mirrors the established protocol for tuberculin skin testing and was adopted by the CDC due to the absence of robust IGRA‑specific conversion data at the time of guideline development. [9][12]
- Emerging research indicates that most IGRA conversions occur 4–7 weeks after exposure, though some contacts may convert as late as 14–22 weeks; nevertheless, the CDC maintains the 8–10‑week window as the standard of care to balance sensitivity with practical implementation. 9
- The CDC’s recommendation of an 8–10‑week repeat test remains the accepted standard of care for TB contact investigations. [9][10]
CDC Recommendations for Tuberculosis Testing After Exposure
Immediate Testing and Symptom Assessment
- Perform a tuberculin skin test (TST) or interferon‑γ release assay (IGRA) as soon as exposure is identified—ideally within the first week for high‑priority contacts—regardless of any prior baseline results. This initial test serves as a reference point but cannot reliably exclude infection if done during the window period. 13
- All exposed individuals should receive a symptom evaluation at the time exposure is recognized, assessing for cough, fever, night sweats, weight loss, and hemoptysis. 13, 14
- Test immediately when exposure is recognized, then repeat testing at 8–10 weeks after the last exposure if the initial test is negative. 13, 14
Repeat Testing (8–10 Weeks Post‑Exposure)
- All contacts with an initial negative result must undergo repeat testing 8–10 weeks after the last exposure, using the same test type (TST or IGRA) as the initial test to avoid false conversions caused by methodological differences. 13, 14